News & Events

Health care in the United States is at a crossroads, said U.S. Food and Drug Administration Commissioner Dr. Robert M. Califf, in large part due to a confluence of post-COVID disinformation, rising cardiovascular mortality rates, a heavier burden of chronic diseases and decreased life expectancy.

New York state however stands out as a bright spot. The state’s success is one of the reasons that brought Dr. Califf...

It may soon be possible to determine which patients with a type of liver cancer called hepatocellular carcinoma would benefit from immunotherapy, according to a preclinical study by Weill Cornell Medicine investigators.

The study, published Oct. 17 in Molecular Cell, provides new insights into a pair of proteins, called p62 and NBR1, and their opposing functions in regulating the interferon response in...

Researchers at Weill Cornell Medicine found that a combination of therapeutic monoclonal antibodies did not reduce the occurrence of long COVID symptoms. The study, published Sept. 1 in eClinicalMedicine, details the first randomized, placebo-controlled phase 2/3 clinical trial evaluating the impact of amubarvimab and romlusevimab--two antibodies used to treat SARS-CoV-2 infection--on the risk...

Immune cells called monocytes produce a key inflammatory protein called interleukin-1 beta (IL-1β) through an unconventional pathway in patients with systemic lupus erythematosus, commonly referred to as lupus, according to a new study by Weill Cornell Medicine investigators.

The findings, published Oct. 7 in Immunity, could lead to new treatments targeting IL-1β to better manage inflammation in patients who don...

Dr. Ali Jalali, an assistant professor of population health sciences at Weill Cornell Medicine, was awarded the prestigious National Institutes of Health (NIH) Director’s New Innovator Award through its Helping to End Addiction...

A new technology enables the control of specific brain circuits non-invasively with magnetic fields, according to a preclinical study from researchers at Weill Cornell Medicine, The Rockefeller University and the Icahn School of Medicine at Mount Sinai. The technology holds promise as a powerful tool for studying the brain and as the basis for future neurological and...

How bladder cancer originates and progresses has been illuminated as never before in a study led by researchers at Weill Cornell Medicine and the New York Genome Center. The researchers found that antiviral enzymes that mutate the DNA of normal and cancer cells are key promoters of early bladder cancer development, and that standard chemotherapy is also a potent source of mutations. The researchers also discovered that overactive genes within abnormal...

Dr. Randy Longman, director of the Jill Roberts Center for Inflammatory Bowel Disease and an associate professor of medicine at Weill Cornell Medicine, and colleagues have received the NIH Director’s...

The possibility of parental disclosure through online patient portals led older adolescents to hesitate in sharing complete health information with doctors, putting them at risk of missed diagnoses and treatments, a new study by Weill Cornell Medicine researchers found.

The...

Removing protected class regulation from Medicare prescription drug policies could greatly reduce the United States' prescription drug spending—this could have saved potentially $47 billion between 2011-2019, according to Weill Cornell Medicine researchers.

The study, published Oct. 7 in Health Affairs, aims to inform policymakers' debates about Medicare Part D covering the expense of all drugs in six "protected...

Dr. Alessandro Fichera, a prominent colorectal surgeon, has been named chief of the Division of Colorectal Surgery at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, effective Oct. 14.

In his new role, Dr. Fichera leads a world-class team of colorectal surgeons that uses state-of-the-art technologies and innovative surgical techniques to provide...

NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine have received the Emergency Medicine Wellness Center of Excellence Award from the American College of Emergency...

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to less invasiveness and weaker biological activity, according to a multicenter study conducted at Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and other institutions.

The...

Weill Cornell Medicine investigators have found that two genetic variants that confer high risk of Alzheimer’s disease (AD) together trigger a harmful inflammatory response in the brain’s immune cells, particularly in females, in a preclinical model.

The findings, published Sept. 30 in Neuron, emphasize the importance of considering sex differences in Alzheimer’s research – a step that could ultimately lead to...

Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune checkpoint inhibitor therapy, according to a preclinical study led by researchers at Weill Cornell Medicine. The findings suggest a potential strategy for enhancing the potency of anticancer immunotherapies.

In the...

A powerful new analytical tool offers a closer look at how tumor cells “shape-shift” to become more aggressive and untreatable, as shown in a study from researchers at Weill Cornell Medicine and the New York Genome Center.

A tumor cell shape-shifts by changing its cell type or state, thus altering its basic pattern of activity and perhaps even its appearance. This changeability or “plasticity” is a characteristic of cancer that leads to diverse...

A new preclinical model using CRISPR, an advanced technology that allows scientists to cut and edit genes, has given Weill Cornell Medicine researchers and their colleagues a deeper insight into how prostate cancer spreads or metastasizes.

In the study, published Sept. 23 in Cancer Discovery, scientists charted the complicated routes...

A multi-institutional clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators showed that a newer technique for collecting prostate biopsy samples reduced the risk of infection compared with traditional biopsy approaches.

The results of the study were published on Sept. 19 in JAMA Oncology.

The technique, called transperineal prostate biopsy, collects prostate tissue via a...

Individuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 virus, which have the potential to spread to the general population, a study by Weill Cornell Medicine, the College of Veterinary Medicine at Cornell University and the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) found.

In the...